FLT3LG and neoplasm: While their frequency returned to the baseline after ISIM, likely due to the trafficking of tumor-residing CD103+ DCs to TdLN (Fig. 1d, e), a second cycle of Flt3L administration restored CD103+ DCs in the tumor (Supplementary Fig. 19b, c), resulting in significantly increased CD8+ TILs, decreased CD11b+ cells, and increased CD8+/CD11b+ cell ratio after a second ISIM treatment (Supplementary Fig. 19d).